MedAvail Holdings, Inc. reaffirmed financial guidance for the full year 2022. The company affirmed its previously issued guidance for full year 2022 revenue to be at least $42 million, representing growth of at least 90% over full year 2021 revenue. The company also affirms its guidance of 40 new net dispensing deployments for full year 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0001 USD | -66.67% |
|
-.--% | -100.00% |
May. 06 | Motion for Asset Sale Filed by MedAvail Holdings, Inc. | CI |
May. 03 | Notice of Successful Bidder Filed by MedAvail Holdings, Inc. | CI |
1st Jan change | Capi. | |
---|---|---|
-100.00% | 161 | |
+11.73% | 86.92B | |
+9.72% | 65.91B | |
+18.15% | 36.73B | |
+17.40% | 32.18B | |
+8.87% | 26.26B | |
-2.20% | 25.59B | |
-1.66% | 25.44B | |
+14.87% | 24.32B | |
-2.53% | 21.32B |
- Stock Market
- Equities
- MYOS Stock
- News MedAvail Holdings, Inc.
- MedAvail Holdings, Inc. Reaffirms Financial Guidance for the Full Year 2022